Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors

Conclusions Afatinib/gemcitabine and afatinib/docetaxel demonstrated manageable safety profiles, with evidence of clinical efficacy at the MTDs. For afatinib/docetaxel, a dose level of afatinib 30  mg/docetaxel 75 mg/m2 produced higher response rates.Trial registration: NCT01251653 (ClinicalTrials.gov).
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research